4SC AG provides results for financial year 2023 and outlook for 2024
4SC AG (4SC, FSE Prime Standard: VSC) today published its financial results for the financial year ended 31 December 202…
4SC AG (4SC, FSE Prime Standard: VSC) today published its financial results for the financial year ended 31 December 202…
4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage c…
The Board of Management of 4SC AG (4SC, FSE Prime Standard: VSC) announced today that according to its best judgment, th…
Phytopharmaceuticals have been a testament to the natural healing power of the plant world since time immemorial. Their…
4SC AG (4SC or "the Company") (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients sufferin…
The European Medicines Agency (EMA) has granted Orphan Drug Designation for resminostat for treatment of cutaneous T…
Positive topline data for resminostat in RESMAIN pivotal study demonstrating 97.6% improvement in progression free survi…
4SC AG (4SC, FSE Prime Standard: VSC) announced that the results from the RESMAIN Study evaluating resminostat (Kinselby…
. The European Medicines Agency (EMA) has notified 4SC that it has accepted its Letter of Intent to Submit a Marketing…
4SC AG (4SC, FSE Prime Standard: VSC) has now filed with EMA its letter of intent to file for Marketing Authorization fo…